Summit Takes Neutral Stance on Risk/Reward Dynamics as Piper Launches Coverage on Biotech Cancer Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2025
0mins
Should l Buy SMMT?
Source: SeekingAlpha
Piper Sandler's Coverage Launch: Piper Sandler initiated coverage on several cancer-focused biotech companies, giving a Neutral rating to Summit Therapeutics (SMMT) due to perceived high investor expectations and downside risks.
Revolution Medicines Rating: Revolution Medicines (RVMD) received an Overweight rating with a target price of $75 per share, driven by positive data for its lead asset daraxonrasib in treating pancreatic ductal adenocarcinoma.
Tango Therapeutics Potential: Analyst Kelsey Goodwin expressed optimism about Tango Therapeutics (TNGX), assigning an Overweight rating and a target of $11 per share, citing potential for its PRMT5-inhibitor TNG462 in various cancers.
UroGen Pharma Outlook: UroGen Pharma (URGN) was also rated Overweight with a target of $36 per share, as confidence grows around the market launch of its bladder cancer drug Zusduri and upcoming clinical updates.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SMMT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SMMT
Wall Street analysts forecast SMMT stock price to rise
12 Analyst Rating
8 Buy
3 Hold
1 Sell
Moderate Buy
Current: 16.590
Low
18.00
Averages
42.49
High
131.90
Current: 16.590
Low
18.00
Averages
42.49
High
131.90
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Summit Therapeutics Announces Upcoming Investor Conference Schedule
- Investor Conference Schedule: Summit Therapeutics will participate in three investor conferences in March 2026, including the TD Cowen Annual Health Care Conference on March 2, showcasing its ongoing developments in the biopharmaceutical sector.
- Ivonescimab Progress: Ivonescimab (SMT112), a novel bispecific antibody, is undergoing multiple Phase III clinical trials, having treated over 4,000 patients globally, demonstrating promising safety and efficacy profiles.
- Clinical Trial Expansion: Summit initiated the HARMONi and HARMONi-3 trials for non-small cell lung cancer (NSCLC) in 2023, with plans to enroll patients in HARMONi-7 starting in 2025, further broadening its clinical development program.
- FDA Application Progress: The Biologics License Application (BLA) for the HARMONi trial was accepted by the FDA in January 2026, with a target approval date of November 14, 2026, marking a significant milestone for the company's market access efforts.
See More
Summit Therapeutics to Participate in Upcoming Investor Conferences
- Investor Conference Participation: Summit Therapeutics will participate in three investor conferences in March 2026, with leadership engaging in individual meetings and fireside chats, aimed at enhancing the company's visibility and credibility among investors.
- ivonescimab Clinical Progress: Ivonescimab (SMT112), a novel bispecific antibody, is involved in 15 Phase III clinical trials, including four globally sponsored by Summit, demonstrating its potential advantages in the tumor microenvironment.
- FDA Application Progress: Summit submitted a Biologics License Application (BLA) for ivonescimab to the FDA in January 2026, with a target PDUFA date of November 14, 2026, which, if approved, could significantly boost the company's revenue.
- Market Potential Assessment: Ivonescimab has been commercially applied to over 60,000 patients in China, indicating broad acceptance in the market and potential economic benefits, further solidifying Summit's position in the global biopharmaceutical sector.
See More
Summit Therapeutics Q4 2025 Earnings Call Highlights
- Clinical Trial Progress: Summit Therapeutics announced the completion of screening for the squamous cohort in the HARMONi-3 study, with an interim PFS analysis planned for Q2 2026, which could accelerate discussions with regulators and potentially lead to earlier approval.
- New Study Launch: The company initiated the ILLUMINE study focusing on PD-L1 positive frontline head and neck squamous cell carcinoma, with enrollment expected to begin next quarter, indicating strong market demand and potential commercial opportunities for new treatment options.
- Strong Financial Position: As of year-end 2025, Summit reported a cash reserve of approximately $713.4 million with no debt, demonstrating financial robustness that supports future clinical trials and expansion plans.
- Operational Efficiency Improvement: Fourth-quarter GAAP operating expenses were $225 million, down from $234.2 million in the third quarter, reflecting the company's effectiveness in controlling spending while providing more funding for subsequent R&D investments.
See More
Summit (SMMT) Q4 2025 Earnings Call Transcript
See More
Summit Therapeutics Reports Q4 Earnings Miss
- Earnings Miss: Summit Therapeutics reported a Q4 non-GAAP EPS of -$0.14, missing expectations by $0.12, indicating ongoing challenges in achieving profitability and investor confidence.
- Cash Position: As of December 31, 2025, the company held $713.4 million in cash and short-term investments, up from $412.3 million in 2024, reflecting improved cash management but highlighting the need for profitability focus.
- FDA Review Progress: The lead asset of Summit is currently under FDA review, and while the market remains optimistic about its potential, the earnings miss could dampen investor sentiment, necessitating close monitoring of future developments.
- Market Reaction: Despite the earnings miss, Summit's stock price spiked due to the FDA review of its lead asset, indicating market expectations for long-term growth potential despite short-term financial setbacks.
See More
US Supreme Court Strikes Down Trump's Tariff Regime
- Market Reaction: The US Supreme Court's 6-3 ruling against Trump's tariff regime led to a swift market rebound, with the S&P 500 rising 0.7%, indicating a moderate investor optimism regarding the policy shift despite initial losses.
- Limited Economic Impact: The ruling affects approximately 60% of tariffs under the IEEPA, and while it could lead to refund requests totaling up to $175 billion, the overall economic impact is deemed limited, resulting in a muted market response.
- Oil Price Fluctuations: Oil prices surged about 5.5% over the past week due to escalating tensions in the Middle East, with projections suggesting a potential increase of $10 to $15 per barrel if the US engages in military action, highlighting the significant geopolitical risks to energy markets.
- Upcoming Economic Data: The forthcoming Producer Price Index (PPI) will provide investors with crucial insights into inflation trends, which are expected to influence the Federal Reserve's monetary policy, particularly as inflation remains persistently above target levels.
See More
Summit Therapeutics Announces Upcoming Investor Conference Schedule
- Investor Conference Schedule: Summit Therapeutics will participate in three investor conferences in March 2026, including the TD Cowen Annual Health Care Conference on March 2, showcasing its ongoing developments in the biopharmaceutical sector.
- Ivonescimab Progress: Ivonescimab (SMT112), a novel bispecific antibody, is undergoing multiple Phase III clinical trials, having treated over 4,000 patients globally, demonstrating promising safety and efficacy profiles.
- Clinical Trial Expansion: Summit initiated the HARMONi and HARMONi-3 trials for non-small cell lung cancer (NSCLC) in 2023, with plans to enroll patients in HARMONi-7 starting in 2025, further broadening its clinical development program.
- FDA Application Progress: The Biologics License Application (BLA) for the HARMONi trial was accepted by the FDA in January 2026, with a target approval date of November 14, 2026, marking a significant milestone for the company's market access efforts.
See More
Summit Therapeutics to Participate in Upcoming Investor Conferences
- Investor Conference Participation: Summit Therapeutics will participate in three investor conferences in March 2026, with leadership engaging in individual meetings and fireside chats, aimed at enhancing the company's visibility and credibility among investors.
- ivonescimab Clinical Progress: Ivonescimab (SMT112), a novel bispecific antibody, is involved in 15 Phase III clinical trials, including four globally sponsored by Summit, demonstrating its potential advantages in the tumor microenvironment.
- FDA Application Progress: Summit submitted a Biologics License Application (BLA) for ivonescimab to the FDA in January 2026, with a target PDUFA date of November 14, 2026, which, if approved, could significantly boost the company's revenue.
- Market Potential Assessment: Ivonescimab has been commercially applied to over 60,000 patients in China, indicating broad acceptance in the market and potential economic benefits, further solidifying Summit's position in the global biopharmaceutical sector.
See More
Summit Therapeutics Q4 2025 Earnings Call Highlights
- Clinical Trial Progress: Summit Therapeutics announced the completion of screening for the squamous cohort in the HARMONi-3 study, with an interim PFS analysis planned for Q2 2026, which could accelerate discussions with regulators and potentially lead to earlier approval.
- New Study Launch: The company initiated the ILLUMINE study focusing on PD-L1 positive frontline head and neck squamous cell carcinoma, with enrollment expected to begin next quarter, indicating strong market demand and potential commercial opportunities for new treatment options.
- Strong Financial Position: As of year-end 2025, Summit reported a cash reserve of approximately $713.4 million with no debt, demonstrating financial robustness that supports future clinical trials and expansion plans.
- Operational Efficiency Improvement: Fourth-quarter GAAP operating expenses were $225 million, down from $234.2 million in the third quarter, reflecting the company's effectiveness in controlling spending while providing more funding for subsequent R&D investments.
See More
Summit (SMMT) Q4 2025 Earnings Call Transcript
See More
Summit Therapeutics Reports Q4 Earnings Miss
- Earnings Miss: Summit Therapeutics reported a Q4 non-GAAP EPS of -$0.14, missing expectations by $0.12, indicating ongoing challenges in achieving profitability and investor confidence.
- Cash Position: As of December 31, 2025, the company held $713.4 million in cash and short-term investments, up from $412.3 million in 2024, reflecting improved cash management but highlighting the need for profitability focus.
- FDA Review Progress: The lead asset of Summit is currently under FDA review, and while the market remains optimistic about its potential, the earnings miss could dampen investor sentiment, necessitating close monitoring of future developments.
- Market Reaction: Despite the earnings miss, Summit's stock price spiked due to the FDA review of its lead asset, indicating market expectations for long-term growth potential despite short-term financial setbacks.
See More
US Supreme Court Strikes Down Trump's Tariff Regime
- Market Reaction: The US Supreme Court's 6-3 ruling against Trump's tariff regime led to a swift market rebound, with the S&P 500 rising 0.7%, indicating a moderate investor optimism regarding the policy shift despite initial losses.
- Limited Economic Impact: The ruling affects approximately 60% of tariffs under the IEEPA, and while it could lead to refund requests totaling up to $175 billion, the overall economic impact is deemed limited, resulting in a muted market response.
- Oil Price Fluctuations: Oil prices surged about 5.5% over the past week due to escalating tensions in the Middle East, with projections suggesting a potential increase of $10 to $15 per barrel if the US engages in military action, highlighting the significant geopolitical risks to energy markets.
- Upcoming Economic Data: The forthcoming Producer Price Index (PPI) will provide investors with crucial insights into inflation trends, which are expected to influence the Federal Reserve's monetary policy, particularly as inflation remains persistently above target levels.
See More
